Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader ParkinsonsDisease Treatment will...
2 Neurodegenerative Diseases Market To 2018: Introduction2.1 Gbi Research Report Guidance3 Neurodegenerative Diseases Mark...
5.2.1 Alzheimers Disease5.2.2 Amyotrophic Lateral Sclerosis5.2.3 Parkinson’s Disease5.2.4 Huntington’s Disease...
6.2.5 Glaxosmithkline Signs An Agreement With Affiris6.2.6 Biogen Enters Into An Agreement With Acorda Therapeutics6.2.7 B...
7.6 Geographical Landscape7.7 Pipeline Analysis7.8 Competitive Landscape7.8.1 Expert Panel Validation7.9 Contact Us7.10 Di...
Upcoming SlideShare
Loading in …5
×

New Depth Study Global Neurodegenerative Diseases Market to 2018

245 views

Published on

Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff”. A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
245
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

New Depth Study Global Neurodegenerative Diseases Market to 2018

  1. 1. Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader ParkinsonsDisease Treatment will Boost Market Despite Patent Cliff GBI Research, the leading business intelligence provider, has released its latest research“Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and BroaderParkinson’s Disease Treatment will Boost Market Despite Patent Cliff”. A highly dynamicmarket scenario is expected in Neurodegenerative diseases in the next few years, with a number of patentexpiries and anticipated new drug approvals. The market for Alzheimer’s disease has not seen anyrecent major breakthroughs, and is expected to experience a decline due to the patent expiry of several majorproducts. The market for Parkinson’s disease, on the other hand, is expected to experience growth dueto the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it willsoon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected toincrease the number of patients suffering from these diseases due to their relatively high prevalence in theelderly. Scope The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top sevendeveloped markets, including the US, Germany, France, the UK, Italy, Spain and Japan. Market data on thegeographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatmentusage patterns such as disease population and prescription populations. Market forecasts for all fourindications across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain-as well as Japan. Key market drivers and barriers The major deals that have taken place in theNeurodegenerative Diseases Market in recent years. Coverage includes Mergers and Acquisitions (M&As) aswell as co-development and licensing agreements, which are segmented on the basis of geography and totalvalue. A concomitant analysis of the licensing deal values for products by molecule types and is also provided. Reasons to Buy Understand the competitive environment for Neurodegenerative Diseases Understand the clinical andcommercial impact of major patent expiries in the neurodegenerative diseases markets Assess the potentialclinical and commercial impact of current late-stage pipeline molecules on the neurodegenerative diseasesmarket in the forecast period Grasp the unmet need which exists in the neurodegenerative diseases MarketExploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gapstable Of Contents1 Table Of Contents1.1 List Of Tables1.2 List Of FiguresNeurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Mar
  2. 2. 2 Neurodegenerative Diseases Market To 2018: Introduction2.1 Gbi Research Report Guidance3 Neurodegenerative Diseases Market To 2018: Global Market Overview3.1 Revenue3.2 Treatment Usage Pattern3.3 Distribution By Market3.4 Drivers And Restraints Of The Neurodegenerative Diseases Market3.4.1 Drivers3.4.2 Restraints4 Therapeutic Landscape4.1 Market For Alzheimer’s Disease4.1.1 Introduction4.1.2 Revenue And Forecasts4.1.3 Treatment Usage Pattern4.1.4 Geographical Landscape4.1.5 Drivers And Restraints For The Alzheimer’s Disease Market4.2 Market For Parkinson’s Disease4.2.1 Introduction4.2.2 Revenue And Forecasts4.2.3 Treatment Usage Pattern4.2.4 Geographical Landscape4.2.5 Drivers And Restraints For The Parkinson’s Disease Market4.3 Market For Amyotrophic Lateral Sclerosis4.3.1 Introduction4.3.2 Revenue And Forecasts4.3.3 Treatment Usage Pattern4.3.4 Geographical Landscape4.3.5 Drivers And Restraints For The Amyotrophic Lateral Sclerosis Market4.4 Market For Huntington’s Disease4.4.1 Introduction4.4.2 Revenue And Forecasts4.4.3 Treatment Usage Pattern4.4.4 Geographical Landscape4.4.5 Drivers And Restraints For The Huntington’s Disease Market5 Neurodegenerative Diseases Market: Pipeline Analysis5.1 Introduction5.2 Summary Of The Current Neurodegenerative Diseases R&d PipelineNeurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Mar
  3. 3. 5.2.1 Alzheimers Disease5.2.2 Amyotrophic Lateral Sclerosis5.2.3 Parkinson’s Disease5.2.4 Huntington’s Disease6 Neurodegenerative Diseases Market: Deals And Strategic Consolidations6.1 Merger And Acquisition Deals6.1.1 Sanofi-synthelabo Merges With Aventis6.1.2 Bayer Acquires Schering6.1.3 Takeda Pharma Completes Acquisition Of Nycomed International For $13,681m6.1.4 Teva Pharma Acquires Ivax6.1.5 Abbott Labs Acquires Solvay Pharma6.1.6 Teva Completes Acquisition Of Cephalon For $6.8 Billion6.1.7 Ucb Acquires 87.62% Stake In Schwarz Pharma6.1.8 Biovail Acquires Valeant Pharma6.1.9 Dainippon Sumitomo Pharma Completes Acquisition Of Sepracor For $2.6 Billion6.1.10 Merck Acquires Banyu Pharma6.1.11 Amgen Completes Acquisition Of Micromet For $1.2 Billion6.1.12 Bayer Acquires Minority Stake In Bayer Schering Pharma6.1.13 Daiichi Sankyo Completes Acquisition Of Plexxikon6.1.14 Lundbeck Acquires Ovation Pharma6.1.15 Eli Lilly And Company Acquires Avid Radiopharma6.1.16 Abbott Labs Completes Acquisition Of Facet Biotech6.1.17 Biogen Idec Acquires Fumapharm6.1.18 Upsher-smith Completes Acquisition Of Remaining 84% Stake In Proximagen For Up To $555m6.1.19 Sun Pharma Acquires Controlling Stake In Taro Pharma6.1.20 Pfizer Acquires Rinat Neuroscience6.1.21 Cubist Pharma Completes Acquisition Of Adolor For $415m6.1.22 Biogen Idec Acquires Panima Pharma6.1.23 Teva Pharma Acquires Cogenesys From New Enterprise, Orbimed And Red Abbey6.1.24 Fujifilm Holdings Acquires 66% Stake In Toyama Chemical6.1.25 Mgi Pharma Acquires Guilford Pharma6.1.26 H. Lundbeck Acquires Lifehealth6.1.27 Endo Pharma Completes Acquisition Of Penwest Pharma6.1.28 Epix Pharma Acquires Predix Pharma6.1.29 Biogen Idec Acquires Syntonix Pharmaceuticals6.1.30 Biotie Therapies Acquires Synosia Therapeutics6.2 Licensing Agreements6.2.1 Cephalon Enters Into A Licensing Agreement With Mesoblast For Regenerative Medicine6.2.2 Idera Pharma Enters Into A Licensing Agreement With Merck6.2.3 Astellas Pharma Enters Into Licensing Agreement With Comentis For Beta-secretase Inhibitors6.2.4 Synosia Therapeutics Enters Into Licensing Agreement With Ucb For Syn-115 And Syn-118Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Mar
  4. 4. 6.2.5 Glaxosmithkline Signs An Agreement With Affiris6.2.6 Biogen Enters Into An Agreement With Acorda Therapeutics6.2.7 Bioms Medical Enters Into Licensing Agreement With Eli Lilly6.2.8 Ac Immune Enters Into Licensing Agreement With Genentech For Anti-tau Antibodies6.2.9 Biovail Enters Into Licensing Agreement With Acadia Pharmaceuticals6.2.10 Biogen Idec Enters Into Licensing Agreement With Knopp Neurosciences For Kns-7607046.2.11 Astrazeneca Enters Into Licensing Agreement With Targacept6.2.12 Ac Immune Enters Into Licensing Agreement With Genentech6.2.13 Proximagen Enters Into Licensing Agreement With Upsher-smith Labs6.2.14 Merck Serono Enters Into Licensing Agreement With Apitope Technology6.2.15 Serono Enters Into Licensing Agreement With Newron Pharma For Safinamide6.2.16 Shire Exercises Option To License Adenosine A2a From Heptares Therapeutics6.2.17 Glaxosmithkline Enters Into Licensing Agreement With Impax Pharma For Ipx0666.2.18 Santhera Pharmaceuticals Enters Into Licensing Agreement With Ipsen For Fipamezole6.2.19 Domain Therapeutics Enters Into Licensing Agreement With Merck Serono6.2.20 Addex Pharma Enters Into Collaboration And Licensing Agreement With Merck & Co6.2.21 Curis Enters Into Licensing Agreement With Wyeth Pharma6.2.22 Pfizer Enters Into A License And Collaboration Agreement With Transtech Pharma6.2.23 Antisense Therapeutics Enters Into Licensing Agreement With Teva Pharma6.2.24 Biogen Idec Enters Into Licensing Agreement With Vernalis6.3 Co-development Deals6.3.1 Glaxosmithkline Signs An Agreement With Targacept6.3.2 Glaxosmithkline Enters Into An Agreement With Epix Pharma6.3.3 Evotec Enters Into Co-development Agreement With Roche6.3.4 Pfizer Enters Into Co-development Agreement With Medivation For Dimebon6.3.5 Alectos Therapeutics Enters Into Research Collaboration With Merck & Co6.3.6 Targacept Expands Its Collaboration Agreement With Astrazeneca6.3.7 Boehringer Ingelheim Partners With Vitae Pharma6.3.8 Elan Enters Into Co-development Agreement With Transition Therapeutics6.3.9 Ceregene Enters Into Agreement With Genzyme7 Appendix7.1 Market Definitions7.2 Abbreviations7.3 Sources7.4 Research Methodology7.4.1 Coverage7.4.2 Secondary Research7.4.3 Primary Research7.5 Therapeutic Landscape7.5.1 Epidemiology-based Forecasting7.5.2 Market Size By GeographyNeurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Mar
  5. 5. 7.6 Geographical Landscape7.7 Pipeline Analysis7.8 Competitive Landscape7.8.1 Expert Panel Validation7.9 Contact Us7.10 DisclaimerAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Mar

×